Rotschild Foundation Hospital and Bulbitech to collaborate on early biomarkers for AMD in NOGA1 study

Sophie Bonnin, MD, PhD is Deputy Head of the Retina Department at the Rothschild Foundation Hospital. Her clinical expertise include retinal diseases, neuro-ophthalmology and clinical imaging. She obtained her MD and internship at the University of Paris VI and her PhD at the Quinze-Vingts Hospital. Her work focused on retinal micro-vascularization studied using high-resolution imaging. She is the author of over 50 medical and scientific articles and is involved in numerous research projects (e.g., retinal imaging, diabetic retinopathy, myopia, optic neuropathies).

Alexandre Dentel is a MD/PhD candidate conducting the NOGA1 clinical study at the Clinical Investigation Center of the Rothschild Foundation Hospital. This study investigates early biomarkers of AMD progression, including Bulbicam tests. His fundamental work on retinal diseases at the Institute of Vision (Sorbonne University) led to the identification of a specific cell death mechanism in cone photoreceptors and to the development of pharmacological treatments preventing cone degeneration in several retinal diseases.